ATXI
Avenue Therapeutics, Inc.0.6749
+0.0243+3.73%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
2.15MP/E (TTM)
0.88Basic EPS (TTM)
0.77Dividend Yield
0%Recent Filings
10-K
FY2025 results
Avenue Therapeutics posted FY2025 net loss of $2.9M, far improved from $11.7M in FY2024, after terminating the AJ201 license in April—yielding $1.4M other revenue—and selling Baergic in November for $0.3M upfront plus milestones (derived). No revenue or quarterly breakdowns disclosed in the 10-K; R&D plunged 84% to $1.0M as AJ201 costs vanished, while G&A fell 21% to $3.7M. Cash holds at $2.9M, but going concern warning flags funding needs for IV tramadol's Phase 3 safety study or ATX-04 pre-IND. No capex, dividends, or buybacks. Fortress controls voting via preferred stock. Baergic sale wiped non-controlling interest.
8-K
Licenses ATX-04 for Pompe
Avenue Therapeutics inked an exclusive worldwide license with Duke University on February 18, 2026, for ATX-04 (clenbuterol) to treat Pompe disease as an ERT adjunct. Backed by Duke's clinical data showing gains in walk distance, muscle strength, and glycogen reduction, Avenue assumes IND and FDA orphan status. Late-stage trials loom. Diligence obligations bind.
8-K
Annual meeting approves directors, auditors
Avenue Therapeutics held its 2025 annual meeting on December 30, electing six directors—Jay Kranzler, Faith Charles, Neil Herskowitz, Alexandra MacLean, Curtis Oltmans, and Lindsay Rosenwald—to serve until 2026, with each garnering over 3.86M votes against minimal withheld. Stockholders also ratified KPMG LLP as independent auditors for the year ending December 31, 2025, by a 3.86M to 105K margin. Directors secured.
8-K
Annual meeting date set
10-Q
Q3 FY2025 results
Avenue Therapeutics narrowed its Q3 operating loss to $724K from $3.2M a year ago, thanks to slashed R&D from $2.3M to $177K after handing AJ201 back to AnnJi; YTD, $1.4M other revenue from that deal offset a $2.3M operating loss, down 76% y/y. Cash climbed to $3.7M on $2.1M ATM proceeds, while ops burned just $979K YTD versus $8.3M prior. No debt. Baergic sold post-quarter to Axsome for $0.3M upfront plus milestones. Losses align across operating and net lines. Thin OTC liquidity poses risks.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ATHA
Athira Pharma, Inc.
3.88+0.03
ATXS
Astria Therapeutics, Inc.
12.87-0.05
AURX
Nuo Therapeutics, Inc.
2.00-0.15
AVDL
Avadel Pharmaceuticals plc
21.37-0.05
AVTX
Avalo Therapeutics, Inc.
18.82+1.12
AVXL
Anavex Life Sciences Corp.
4.02-0.12
GRCE
Grace Therapeutics, Inc.
3.34+0.10
NRXS
Neuraxis, Inc.
2.70+0.05
XRTX
XORTX Therapeutics Inc.
0.59-0.01